Cargando…
Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons?
INTRODUCTION: Zinc chelators were shown to facilitate some opioid-withdrawal signs in animals. Zinc deficiency, which affects more than 15 % the world’s population, is also common among opioid consumers and opioid-treated animals exhibit misbalances of zinc distribution. AIM: The present study focus...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523930/ https://www.ncbi.nlm.nih.gov/pubmed/26238243 http://dx.doi.org/10.1186/s13011-015-0025-2 |
_version_ | 1782384137635627008 |
---|---|
author | Ciubotariu, Diana Ghiciuc, Cristina Mihaela Lupușoru, Cătălina Elena |
author_facet | Ciubotariu, Diana Ghiciuc, Cristina Mihaela Lupușoru, Cătălina Elena |
author_sort | Ciubotariu, Diana |
collection | PubMed |
description | INTRODUCTION: Zinc chelators were shown to facilitate some opioid-withdrawal signs in animals. Zinc deficiency, which affects more than 15 % the world’s population, is also common among opioid consumers and opioid-treated animals exhibit misbalances of zinc distribution. AIM: The present study focuses on how zinc ions interfere with opioid dependence/addiction and analgesia, trying to preliminary discuss if zinc supplementation in opioid-users should be recommended in order to reduce the risk of addiction. METHODS: All relevant literature was searched up to April 2015. The search was performed using the term “zinc” plus combinations of following terms: “opioid receptors”, “opioid” or representatives of this class, “addiction”, “dependence”, “analgesia”, and “pain”. Human, animal, in vitro studies and reviews were including. RESULTS: Both human and animal studies revealed decreased serum zinc under opioid-administration conditions, attributed mainly to increased urinary elimination (humans) or redistribution (animals). Moreover, animal studies revealed decreased brain zinc levels in morphine-treated animals, with increased zinc hepatic levels, but also an enhancement of endogenous opioid system activity and a possible reduction of morphine withdrawal by zinc. In vitro studies revealed reduction of opioid ligands binding to receptors by zinc. However, the very few in vivo animal studies on opioid analgesia revealed controversial results, as zinc demonstrated clear analgesic effect, but zinc associated to opioids doesn’t result in a potentiation of the analgesic effect. CONCLUSION: Zinc dietary supplementation in patients treated with opioids for cancer-related chronic pain should be considered, due to the high incidence of zinc deficiency, also well-documented in opioid consumers. The low toxicity of orally-administered zinc also pleads for this idea. The main contra-argument to zinc administration in opioid-treated persons is related to the way zinc influences opioid-induced analgesia. |
format | Online Article Text |
id | pubmed-4523930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45239302015-08-05 Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? Ciubotariu, Diana Ghiciuc, Cristina Mihaela Lupușoru, Cătălina Elena Subst Abuse Treat Prev Policy Review INTRODUCTION: Zinc chelators were shown to facilitate some opioid-withdrawal signs in animals. Zinc deficiency, which affects more than 15 % the world’s population, is also common among opioid consumers and opioid-treated animals exhibit misbalances of zinc distribution. AIM: The present study focuses on how zinc ions interfere with opioid dependence/addiction and analgesia, trying to preliminary discuss if zinc supplementation in opioid-users should be recommended in order to reduce the risk of addiction. METHODS: All relevant literature was searched up to April 2015. The search was performed using the term “zinc” plus combinations of following terms: “opioid receptors”, “opioid” or representatives of this class, “addiction”, “dependence”, “analgesia”, and “pain”. Human, animal, in vitro studies and reviews were including. RESULTS: Both human and animal studies revealed decreased serum zinc under opioid-administration conditions, attributed mainly to increased urinary elimination (humans) or redistribution (animals). Moreover, animal studies revealed decreased brain zinc levels in morphine-treated animals, with increased zinc hepatic levels, but also an enhancement of endogenous opioid system activity and a possible reduction of morphine withdrawal by zinc. In vitro studies revealed reduction of opioid ligands binding to receptors by zinc. However, the very few in vivo animal studies on opioid analgesia revealed controversial results, as zinc demonstrated clear analgesic effect, but zinc associated to opioids doesn’t result in a potentiation of the analgesic effect. CONCLUSION: Zinc dietary supplementation in patients treated with opioids for cancer-related chronic pain should be considered, due to the high incidence of zinc deficiency, also well-documented in opioid consumers. The low toxicity of orally-administered zinc also pleads for this idea. The main contra-argument to zinc administration in opioid-treated persons is related to the way zinc influences opioid-induced analgesia. BioMed Central 2015-08-04 /pmc/articles/PMC4523930/ /pubmed/26238243 http://dx.doi.org/10.1186/s13011-015-0025-2 Text en © Ciubotariu et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Ciubotariu, Diana Ghiciuc, Cristina Mihaela Lupușoru, Cătălina Elena Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? |
title | Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? |
title_full | Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? |
title_fullStr | Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? |
title_full_unstemmed | Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? |
title_short | Zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? |
title_sort | zinc involvement in opioid addiction and analgesia – should zinc supplementation be recommended for opioid-treated persons? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4523930/ https://www.ncbi.nlm.nih.gov/pubmed/26238243 http://dx.doi.org/10.1186/s13011-015-0025-2 |
work_keys_str_mv | AT ciubotariudiana zincinvolvementinopioidaddictionandanalgesiashouldzincsupplementationberecommendedforopioidtreatedpersons AT ghiciuccristinamihaela zincinvolvementinopioidaddictionandanalgesiashouldzincsupplementationberecommendedforopioidtreatedpersons AT lupusorucatalinaelena zincinvolvementinopioidaddictionandanalgesiashouldzincsupplementationberecommendedforopioidtreatedpersons |